POLE and colorectal carcinoma: Beyond that, for some popular immunotherapy biomarkers in CRC, including TMB, MSI, ICPs expression and POLE mutations, we found their distribution in the ‘Double‐Hit’ phenotype were more conducive to obtaining an effective immunotherapy response.